{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:09:21Z","timestamp":1793686161718,"version":"4.5.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012621","name":"NIHR UCLH BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jiac.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T03:09:13Z","timestamp":1649905753000},"page":"948-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19"],"prefix":"10.1016","volume":"28","author":[{"given":"Timothy Arthur Chandos","family":"Snow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Longobardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-3379","authenticated-orcid":false,"given":"David","family":"Brealey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Down","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0120-7885","authenticated-orcid":false,"given":"Giovanni","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishkantha","family":"Arulkumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jiac.2022.04.001_bib1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1164\/rccm.202008-3148LE","article-title":"Immunomodulators in COVID-19: two sides to every coin","volume":"202","author":"Snow","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jiac.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","article-title":"Immunomodulation by macrolides: therapeutic potential for critical care","volume":"8","author":"Reijnders","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"16","key":"10.1016\/j.jiac.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1093\/cid\/ciaa606","article-title":"Reduction of Coronavirus burden with mass azithromycin distribution","volume":"71","author":"Doan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10256","key":"10.1016\/j.jiac.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jiac.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"issue":"2348","key":"10.1016\/j.jiac.2022.04.001_bib6","article-title":"Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients","volume":"11","author":"Hu","year":"2020","journal-title":"Original Res"},{"issue":"10234","key":"10.1016\/j.jiac.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jiac.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat Med"},{"issue":"2599","key":"10.1016\/j.jiac.2022.04.001_bib9","article-title":"The role of type I interferons in the pathogenesis and treatment of COVID-19","volume":"11","author":"Schreiber","year":"2020","journal-title":"Review"},{"key":"10.1016\/j.jiac.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcrc.2020.11.012","article-title":"COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study","volume":"62","author":"Longobardo","year":"2020","journal-title":"J Crit Care"},{"issue":"8","key":"10.1016\/j.jiac.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"10.1016\/j.jiac.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1038\/srep07438","article-title":"Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity","volume":"4","author":"Ratzinger","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2022.04.001_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/srep12016","article-title":"Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation","volume":"5","author":"Gualdoni","year":"2015","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jiac.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jiac.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2022.04.001_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198005","article-title":"Co-infection with respiratory pathogens among COVID-2019 cases","volume":"285","author":"Zhu","year":"2020","journal-title":"Virus Res"},{"key":"10.1016\/j.jiac.2022.04.001_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-021-00505-8","article-title":"Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label single-arm trial","author":"Tsiakos","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.jiac.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1248\/bpb.31.217","article-title":"Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells","volume":"31","author":"Miyamoto","year":"2008","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.jiac.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1097\/CCM.0000000000004363","article-title":"Surviving sepsis campaign: Guidelines on the management of critically ill adults with Coronavirus disease 2019 (COVID-19)","volume":"48","author":"Alhazzani","year":"2020","journal-title":"Crit Care Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:04:07Z","timestamp":1761159847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2200109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1341321X2200109X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.04.001","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}